A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities

Xuemei Liao,1,* Hui Ye,2,* Tianmei Si1 1Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, People&rsqu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liao X, Ye H, Si T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	antipsychotics switch metabolic syndrome Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/2bc95ce15fe142eda43fbcfdde51a676
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2bc95ce15fe142eda43fbcfdde51a676
record_format	dspace
spelling	oai:doaj.org-article:2bc95ce15fe142eda43fbcfdde51a6762021-12-02T12:14:52ZA Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities1178-2021https://doaj.org/article/2bc95ce15fe142eda43fbcfdde51a6762021-02-01T00:00:00Zhttps://www.dovepress.com/a-review-of-switching-strategies-for-patients-with-schizophrenia-comor-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Xuemei Liao,1,* Hui Ye,2,* Tianmei Si1 1Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, People’s Republic of China; 2Medical Department, Sanofi, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Tianmei SiPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Huayuanbeilu 51#, Haidian District, Beijing, 100191, People’s Republic of ChinaTel +86 13910987793Email si.tian-mei@163.comAbstract: Metabolic syndrome (MetS) in patients with schizophrenia occurs 2– 3 times more frequently than in the general population. Antipsychotic medication is a primary risk factor for patients with MetS. In particular, the widely used second-generation antipsychotics can affect glucose and lipid metabolism and can induce insulin resistance and other metabolic abnormalities through various receptors. Notably, the metabolic risks of various antipsychotics may differ because of their different pharmacological affinity to MetS-related receptors. Several previous studies have shown that switching from high to low metabolic risk antipsychotics may improve patients’ metabolic parameters. The current review aims to discuss the strategies for switching antipsychotic medications and the impact on metabolic abnormalities in patients with schizophrenia.Keywords: antipsychotics, switch, metabolic syndromeLiao XYe HSi TDove Medical Pressarticleantipsychoticsswitchmetabolic syndromeNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 453-469 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antipsychotics switch metabolic syndrome Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	antipsychotics switch metabolic syndrome Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Liao X Ye H Si T A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities
description	Xuemei Liao,1,* Hui Ye,2,* Tianmei Si1 1Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, People’s Republic of China; 2Medical Department, Sanofi, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Tianmei SiPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Huayuanbeilu 51#, Haidian District, Beijing, 100191, People’s Republic of ChinaTel +86 13910987793Email si.tian-mei@163.comAbstract: Metabolic syndrome (MetS) in patients with schizophrenia occurs 2– 3 times more frequently than in the general population. Antipsychotic medication is a primary risk factor for patients with MetS. In particular, the widely used second-generation antipsychotics can affect glucose and lipid metabolism and can induce insulin resistance and other metabolic abnormalities through various receptors. Notably, the metabolic risks of various antipsychotics may differ because of their different pharmacological affinity to MetS-related receptors. Several previous studies have shown that switching from high to low metabolic risk antipsychotics may improve patients’ metabolic parameters. The current review aims to discuss the strategies for switching antipsychotic medications and the impact on metabolic abnormalities in patients with schizophrenia.Keywords: antipsychotics, switch, metabolic syndrome
format	article
author	Liao X Ye H Si T
author_facet	Liao X Ye H Si T
author_sort	Liao X
title	A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities
title_short	A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities
title_full	A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities
title_fullStr	A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities
title_full_unstemmed	A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities
title_sort	review of switching strategies for patients with schizophrenia comorbid with metabolic syndrome or metabolic abnormalities
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/2bc95ce15fe142eda43fbcfdde51a676
work_keys_str_mv	AT liaox areviewofswitchingstrategiesforpatientswithschizophreniacomorbidwithmetabolicsyndromeormetabolicabnormalities AT yeh areviewofswitchingstrategiesforpatientswithschizophreniacomorbidwithmetabolicsyndromeormetabolicabnormalities AT sit areviewofswitchingstrategiesforpatientswithschizophreniacomorbidwithmetabolicsyndromeormetabolicabnormalities AT liaox reviewofswitchingstrategiesforpatientswithschizophreniacomorbidwithmetabolicsyndromeormetabolicabnormalities AT yeh reviewofswitchingstrategiesforpatientswithschizophreniacomorbidwithmetabolicsyndromeormetabolicabnormalities AT sit reviewofswitchingstrategiesforpatientswithschizophreniacomorbidwithmetabolicsyndromeormetabolicabnormalities
_version_	1718394562895937536

A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities

Ejemplares similares